CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 8.62; value investors should ...

Spark’s Take on GB:GSK Stock According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform. GlaxoSmithKline’s stock is supported by strong financial performance and strategic initiatives ...

GSK also boasts an average earnings surprise of 8.6%. With a solid Zacks Rank and top-tier Value and VGM Style Scores, GSK should be on investors' short list. Don’t Miss Out on These Stocks ...

Read GSK PLC Sponsored ADR (NYSE:GSK) ... The institutional investor owned 305,395 shares of the pharmaceutical company’s stock after buying an additional 13,239 shares ...